Literature DB >> 373542

The Philadelphia epidemic of Legionnaire's disease: clinical, pulmonary, and serologic findings two years later.

G L Lattimer, L V Rhodes, J S Salventi, J P Galgon, V Stonebraker, S Boley, G Haas.   

Abstract

Clinical, pulmonary, and serologic findings in Legionnaires who attended the 1976 American Legion Convention in Philadelphia were studied 2 years after the Legionnaires' disease epidemic there. All 31 survivors of Legionnaires' disease studied became ill within 2 weeks after the convention, and 18 had not fully recovered 2 years after the epidemic. Twenty-five (28%) of 90 additional Legionnaires exposed at the convention but not diagnosed as having Legionnaires' disease became ill during the same time interval; five of these had symptoms during the next 2 years. Survivors had decreased diffusion capacities measured by the carbon monoxide single-breath method. These differences could not be accounted for by ventilation abnormalities or concurrent illness. Significant levels of IgG or IgM antibodies persisted in 94% of survivors of Legionnaires' disease and in 53% of Legionnaires exposed at the convention, which suggests a high prevalence of subclinical infection. Persistence of IgM antibody raises the question of latency or subclinical infection as part of the natural history of Legionnaires' disease.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 373542     DOI: 10.7326/0003-4819-90-4-522

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  10 in total

1.  Extremely elevated erythrocyte sedimentation rates (ESRs) in Legionnaires' disease.

Authors:  B A Cunha; S Strollo; P Schoch
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-07-22       Impact factor: 3.267

2.  Seroepidemiological study after a long-distance industrial outbreak of legionnaires' disease.

Authors:  E Wedege; T Bergdal; K Bolstad; D A Caugant; J Efskind; H E Heier; A Kanestrøm; B H Strand; I S Aaberge
Journal:  Clin Vaccine Immunol       Date:  2009-02-18

3.  Persistence of the bacterial pathogen Granulibacter bethesdensis in chronic granulomatous disease monocytes and macrophages lacking a functional NADPH oxidase.

Authors:  Jessica Chu; Helen H Song; Kol A Zarember; Teresa A Mills; John I Gallin
Journal:  J Immunol       Date:  2013-08-16       Impact factor: 5.422

4.  Serum antibodies to Legionella agents in bronchial asthma.

Authors:  S Beer; I Boldur; R Kazak; S Avidan; Y Kannai
Journal:  Arch Dis Child       Date:  1985-03       Impact factor: 3.791

5.  Estimation of minimum infection rates with Legionella pneumophila in an exposed population.

Authors:  H C Boshuizen; N J D Nagelkerke; J W Den Boer; H De Melker; J F P Schellekens; M F Peeters; H Van Vliet; M A E Conyn-Van Spaendonck
Journal:  Epidemiol Infect       Date:  2005-10-20       Impact factor: 2.451

6.  Legionnaires' disease serology. Effect of antigen preparation on specificity and sensitivity of the indirect fluorescent antibody test.

Authors:  G L Lattimer; B A Cepil
Journal:  J Clin Pathol       Date:  1980-06       Impact factor: 3.411

7.  Characterization of the extent of a large outbreak of Legionnaires' disease by serological assays.

Authors:  Øystein Simonsen; Elisabeth Wedege; Anita Kanestrøm; Karin Bolstad; Ingeborg S Aaberge; Eivind Ragnhildstveit; Jetmund Ringstad
Journal:  BMC Infect Dis       Date:  2015-03-28       Impact factor: 3.090

8.  Motor neuron disease mortality rates in U.S. states are associated with well water use.

Authors:  Gary G Schwartz; Marilyn G Klug
Journal:  Amyotroph Lateral Scler Frontotemporal Degener       Date:  2016-06-21       Impact factor: 4.092

Review 9.  Indoor air quality and human health: truth vs mass hysteria.

Authors:  Christopher Chang; M Eric Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2004-12       Impact factor: 8.667

10.  Assessing the long-term health impact of Q-fever in the Netherlands: a prospective cohort study started in 2007 on the largest documented Q-fever outbreak to date.

Authors:  Joris Af van Loenhout; W John Paget; Jan H Vercoulen; Clementine J Wijkmans; Jeannine L A Hautvast; Koos van der Velden
Journal:  BMC Infect Dis       Date:  2012-10-30       Impact factor: 3.090

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.